title: Can genomic medicine improve financial sustainability of health systems?
abstract: Recent years have seen increased use of genomic technologies in a variety of research and clinical settings. Genomic medicine is not a cost-containment measure per se, but is viewed as having the potential to bend the healthcare cost curve. Currently, it is unknown how systematic adoption of genomic medicine in clinical practice will impact healthcare costs. This article discusses the potential economic impact of genomic medicine and the challenges that lie ahead.
authors: Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, 6th Floor, 133 Brookline Ave, Boston, MA, 02215, USA, christine_lu@harvardpilgrim.org.
authors: Christine Y
authors: CY
authors: Lu
authors: Joshua P
authors: JP
authors: Cohen
mesh_terms: D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care / Q000191:economics* / Q000379:methods*; D023281:Genomics / Q000191:economics / Q000379:methods; D017048:Health Care Costs; D006801:Humans; D008511:Medicine